KYMR — Kymera Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1815442 ·
Last close
$80.77
Market Cap
$6.64B
52W High
$93.99
52W Low
$73.31
ADV30
503,647
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 34,365,000 | — | -84,154,000 | -69,234,000 | 1,669,016,000 | 144,090,000 | 129,379,000 |
| Dec 2025 | 2,870,000 | — | -97,896,000 | -86,981,000 | 1,742,812,000 | 357,011,000 | 163,148,000 |
| Sep 2025 | 2,764,000 | — | -88,666,000 | -82,175,000 | 1,102,044,000 | 112,949,000 | 155,786,000 |
| Jun 2025 | 11,476,000 | — | -84,557,000 | -76,614,000 | 1,131,068,000 | 335,816,000 | 159,588,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-242,581,000
Investing CF
$-712,516,000
Financing CF
$1,009,224,000
CapEx
$-1,416,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.57
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,135,195,000
Inventory
—
Receivables
—
ST Investments
$506,839,000
EBIT TTM
$-314,647,000
Pretax Income TTM
$-315,004,000
Interest Exp TTM
$357,000
Analysts
22
Yahoo Snapshot (yfinance, live)
Total Revenue
$51,476,000
EBITDA
$-348,584,992
Free Cash Flow
$-139,262,368
Enterprise Value
$5,918,841,344
Total Cash
$650,929,024
Total Debt
$80,469,000
Shares Out
82,257,588
Trailing EPS
$-3.58
Book Value
$19.42
ROE
-27.1%
ROA
-17.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 39,211,000 | -345,544,000 | -311,351,000 | 1,742,812,000 | 163,148,000 | — | -232,891,000 |
| Dec 2024 | 47,072,000 | -256,710,000 | -223,858,000 | 978,035,000 | 142,416,000 | — | -194,501,000 |
| Dec 2023 | 78,592,000 | -165,530,000 | -146,962,000 | 575,759,000 | 180,788,000 | — | -102,826,000 |
| Dec 2022 | 46,826,000 | -161,256,000 | -154,808,000 | 603,134,000 | 112,983,000 | — | -153,085,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.37
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RGEN | REPLIGEN CORP | $6.50B | $115.19 | — |
| IMVT | Immunovant, Inc. | $6.95B | $33.83 | — |
| SRRK | Scholar Rock Holding Corp | $6.17B | $51.51 | — |
| PCVX | Vaxcyte, Inc. | $7.24B | $50.11 | — |
| QGEN | QIAGEN N.V. | $7.33B | $35.54 | — |
News headlines (Yahoo Finance, 1h cache)
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data
2026-05-26 13:06 · Yahoo
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
2026-05-17 20:46 · Yahoo
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
2026-05-17 20:07 · Yahoo
Kymera Therapeutics (KYMR) Valuation Check After New KT-621 And KT-579 Clinical And Preclinical Progress
2026-05-15 16:14 · Yahoo
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
2026-05-15 11:00 · Yahoo
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma
2026-05-14 19:05 · Yahoo
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO
2026-05-14 18:57 · Yahoo
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700%
2026-05-14 18:51 · Yahoo
How The Kymera Therapeutics (KYMR) Story Is Shifting Around KT-621 And Degrader Potential
2026-05-07 17:12 · Yahoo
AMD upgraded, Reddit downgraded: Wall Street's top analyst calls
2026-05-06 13:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.